Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Trans-counseling: A case series of transgender individuals at high risk for BRCA1 pathogenic variants.

Sacca RE, Koeller DR, Rana HQ, Garber JE, Morganstern DE.

J Genet Couns. 2019 Jun;28(3):708-716. doi: 10.1002/jgc4.1046. Epub 2019 Jan 24.

PMID:
30680866
2.

Cancer genetic counselors' experiences with transgender patients: A qualitative study.

Zayhowski K, Park J, Boehmer U, Gabriel C, Berro T, Campion M.

J Genet Couns. 2019 Jun;28(3):641-653. doi: 10.1002/jgc4.1092. Epub 2019 Feb 5.

PMID:
30720922
3.

BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer.

Petrucelli N, Daly MB, Pal T.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
1998 Sep 4 [updated 2016 Dec 15].

4.

Cancer prevention and screening practices among women at risk for hereditary breast and ovarian cancer after genetic counseling in the community setting.

Morgan D, Sylvester H, Lucas FL, Miesfeldt S.

Fam Cancer. 2009;8(4):277-87. doi: 10.1007/s10689-009-9242-z. Epub 2009 Apr 4.

PMID:
19347608
5.

Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result.

Vos J, Gómez-García E, Oosterwijk JC, Menko FH, Stoel RD, van Asperen CJ, Jansen AM, Stiggelbout AM, Tibben A.

Psychooncology. 2012 Jan;21(1):29-42. doi: 10.1002/pon.1864. Epub 2010 Nov 11.

PMID:
21072753
6.

Intentions for risk-reducing surgery among high-risk women referred for BRCA1/BRCA2 genetic counseling.

Tong A, Kelly S, Nusbaum R, Graves K, Peshkin BN, Valdimarsdottir HB, Wood M, McKinnon W, Garber J, McCormick SR, Jandorf L, Schwartz MD.

Psychooncology. 2015 Jan;24(1):33-9. doi: 10.1002/pon.3560. Epub 2014 May 17.

7.

Breast cancer and its impact in male transsexuals.

Nikolić D, Granić M, Ivanović N, Zdravković D, Nikolić A, Stanimirović V, Zdravković M, Dikić S, Nikolić M, Djordjević M.

Breast Cancer Res Treat. 2018 Oct;171(3):565-569. doi: 10.1007/s10549-018-4875-y. Epub 2018 Jul 5. Review.

PMID:
29974289
8.

Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.

Catts ZA, Baig MK, Milewski B, Keywan C, Guarino M, Petrelli N.

Ann Surg Oncol. 2016 May;23(5):1729-35. doi: 10.1245/s10434-015-5026-x. Epub 2016 Jan 4.

PMID:
26727920
9.

Genetic Tests for Breast and Ovarian Cancer [Internet].

Juvet LK, Natvig Norderhaug I.

Oslo, Norway: Knowledge Centre for the Health Services at The Norwegian Institute of Public Health (NIPH); 2008 Feb.

10.

Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing.

Lerman C, Biesecker B, Benkendorf JL, Kerner J, Gomez-Caminero A, Hughes C, Reed MM.

J Natl Cancer Inst. 1997 Jan 15;89(2):148-57.

PMID:
8998184
12.

Physicians' experiences with BRCA1/2 testing in community settings.

Keating NL, Stoeckert KA, Regan MM, DiGianni L, Garber JE.

J Clin Oncol. 2008 Dec 10;26(35):5789-96. doi: 10.1200/JCO.2008.17.8053. Epub 2008 Nov 10.

13.

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.

Kuusisto KM, Bebel A, Vihinen M, Schleutker J, Sallinen SL.

Breast Cancer Res. 2011 Feb 28;13(1):R20. doi: 10.1186/bcr2832.

14.

Uptake, Results, and Outcomes of Germline Multiple-Gene Sequencing After Diagnosis of Breast Cancer.

Kurian AW, Ward KC, Hamilton AS, Deapen DM, Abrahamse P, Bondarenko I, Li Y, Hawley ST, Morrow M, Jagsi R, Katz SJ.

JAMA Oncol. 2018 Aug 1;4(8):1066-1072. doi: 10.1001/jamaoncol.2018.0644.

15.

Hereditary diffuse gastric cancer and lynch syndromes in a BRCA1/2 negative breast cancer patient.

Njoroge SW, Burgess KR, Cobleigh MA, Alnajar HH, Gattuso P, Usha L.

Breast Cancer Res Treat. 2017 Nov;166(1):315-319. doi: 10.1007/s10549-017-4393-3. Epub 2017 Jul 12.

PMID:
28702897
16.

Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients.

Schwartz MD, Lerman C, Brogan B, Peshkin BN, Halbert CH, DeMarco T, Lawrence W, Main D, Finch C, Magnant C, Pennanen M, Tsangaris T, Willey S, Isaacs C.

J Clin Oncol. 2004 May 15;22(10):1823-9. Epub 2004 Apr 5.

PMID:
15067026
17.

Hormonal and surgical treatment in trans-women with BRCA1 mutations: a controversial topic.

Colebunders B, T'Sjoen G, Weyers S, Monstrey S.

J Sex Med. 2014 Oct;11(10):2496-9. doi: 10.1111/jsm.12628. Epub 2014 Jul 10.

PMID:
25042481
18.

American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.

American Society of Clinical Oncology.

J Clin Oncol. 2003 Jun 15;21(12):2397-406. Epub 2003 Apr 11.

PMID:
12692171
19.

A survey of genetic counselors about the needs of 18-25 year olds from families with hereditary breast and ovarian cancer syndrome.

Werner-Lin A, Ratner R, Hoskins LM, Lieber C.

J Genet Couns. 2015 Feb;24(1):78-87. doi: 10.1007/s10897-014-9739-y. Epub 2014 Jul 12.

PMID:
25011978
20.

Randomized trial of proactive rapid genetic counseling versus usual care for newly diagnosed breast cancer patients.

Schwartz MD, Peshkin BN, Isaacs C, Willey S, Valdimarsdottir HB, Nusbaum R, Hooker G, O'Neill S, Jandorf L, Kelly SP, Heinzmann J, Zidell A, Khoury K.

Breast Cancer Res Treat. 2018 Aug;170(3):517-524. doi: 10.1007/s10549-018-4773-3. Epub 2018 Apr 2.

PMID:
29611029

Supplemental Content

Support Center